Skip to main content

Table 3 Multivariate Cox regression analysis for the relationship between blood lead levels with all-cause and cardiovascular disease mortality

From: Association of low-level lead exposure with all-cause and cardiovascular disease mortality in US adults with hypertension: evidence from the National Health and Nutrition Examination Survey 2003–2010

 

Model 1 HR(95%CI) P

Model 2 HR(95%CI) P

Model 3 HR(95%CI) P

All-cause mortality

 Continuous

1.46 ( 1.40, 1.52) < 0.001

1.25 ( 1.19, 1.30) < 0.001

1.23 ( 1.16, 1.30) < 0.001

 Lead quartiles

  Q1

1.0

1.0

1.0

  Q2

1.51 ( 1.21, 1.89) < 0.001

1.14 ( 0.93, 1.39) 0.22

1.21 ( 0.99, 1.48) 0.06

  Q3

1.94 ( 1.61, 2.33) < 0.001

1.21 ( 1.00, 1.46) 0.05

1.26 ( 1.05, 1.52) 0.01

  Q4

3.06 ( 2.61, 3.60) < 0.001

1.75 ( 1.47, 2.08) < 0.001

1.73 ( 1.43, 2.10) < 0.001

  p for trend

 < 0.001

 < 0.001

 < 0.001

Cardiovascular disease mortality

 Continuous

1.60 ( 1.48, 1.72) < 0.001

1.35 ( 1.24, 1.48) < 0.001

1.34 ( 1.21, 1.48) < 0.001

 Lead quartiles

  Q1

1.0

1.0

1.0

  Q2

1.59 ( 1.11, 2.26) 0.01

1.13 ( 0.80, 1.60) 0.47

1.22 ( 0.87, 1.72) 0.24

  Q3

2.20 ( 1.64, 2.96) < 0.001

1.26 ( 0.93, 1.72) 0.14

1.32 ( 0.95, 1.83) 0.09

  Q4

3.83 ( 2.91, 5.05) < 0.001

2.01 ( 1.51, 2.67) < 0.001

2.00 ( 1.47, 2.73) < 0.001

  p for trend

 < 0.001

 < 0.001

0.005

  1. HR Hazard Ratio, CI Confidence interval
  2. Model 1: Unadjusted model
  3. Model 2: Adjusted for sex, age and race
  4. Model 3: Confounders such as body mass index, education level, poverty income ratio, systolic blood pressure, diastolic blood pressure, smoker, drinker, estimated glomerular filtration rate, diabetes, cardiovascular disease, hyperlipidemia, cancer, antidiabetic drugs, antihypertensive drugs, antihyperlipidemic drugs, and antiplatelet drugs, were further adjusted on the basis of Model 2